Gain Therapeutics, Inc. (GANX)
| Market Cap | 58.05M -15.0% |
| Revenue (ttm) | n/a |
| Net Income | -20.11M |
| EPS | -0.51 |
| Shares Out | 43.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 510,725 |
| Open | 1.320 |
| Previous Close | 1.320 |
| Day's Range | 1.310 - 1.410 |
| 52-Week Range | 1.295 - 4.340 |
| Beta | 0.19 |
| Analysts | Strong Buy |
| Price Target | 7.20 (+441.35%) |
| Est. Earnings | Nov 11, 2026 |
About GANX
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company’s drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price target is $7.2, which is an increase of 441.35% from the latest price.
News
Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
Milan, Italy, October 13, 2026 – Sibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial Of...
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration o...
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the n...
Gain Therapeutics Earnings release: Q2 2026
Gain Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Gain Therapeutics Quarterly report: Q2 2026
Gain Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Gain Therapeutics reports Q2 EPS (11c), consensus (15c)
“The second quarter marked an important period of execution for Gain, highlighted by FDA authorization of our IND for rexaceract, which positions us to advance into Phase 2 clinical development,”…
Gain Therapeutics Slides: Corporate presentation
Gain Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics receives FDA clearance of GT-02287 IND application
Gain Therapeutics (GANX) announced that the FDA has authorized the company’s investigational new drug, or IND, application for GT-02287. The FDA’s decision will allow initiation of the company’s Phase...
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26
Gain Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
GT-02287, an AI-discovered GCase modulator, has shown safety, biomarker-driven efficacy, and stabilization of Parkinson's symptoms in early trials. Phase II is set for next quarter, with a focus on clinical and biomarker endpoints, and the company is exploring financing and partnership options.
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Gain Therapeutics Slides: Corporate presentation
Gain Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Gain Therapeutics presents data from Phase 1b study of GT-02287
Gain Therapeutics (GANX) announced the presentation of an oral presentation at the 3rd International GBA1 Meeting 2026, held May 22-23, 2026, in Phoenix, AZ. The oral presentation outlined new clinica...
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph cont...
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Gain Therapeutics (GANX) to $8 from $10 but keeps a Buy rating on the shares. The company’s GT-02287 program…
Gain Therapeutics Earnings release: Q1 2026
Gain Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Gain Therapeutics Quarterly report: Q1 2026
Gain Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
“The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and…
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the n...
Gain Therapeutics Slides: Corporate presentation
Gain Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Gain Therapeutics Proxy statement: Proxy filing
Gain Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.